| TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance L Silwal-Pandit, HKM Vollan, SF Chin, OM Rueda, S McKinney, T Osako, ... Clinical Cancer Research 20 (13), 3569-3580, 2014 | 338 | 2014 |
| TP53 mutations in breast and ovarian cancer L Silwal-Pandit, A Langerød, AL Børresen-Dale Cold Spring Harbor perspectives in medicine 7 (1), a026252, 2017 | 187 | 2017 |
| Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells NT Pfister, V Fomin, K Regunath, JY Zhou, W Zhou, L Silwal-Pandit, ... Genes & development 29 (12), 1298-1315, 2015 | 158 | 2015 |
| TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients AR Halvorsen, L Silwal-Pandit, LA Meza-Zepeda, D Vodak, P Vu, ... Frontiers in genetics 7, 85, 2016 | 96 | 2016 |
| Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53 D Quigley, L Silwal-Pandit, R Dannenfelser, A Langerød, HKM Vollan, ... Molecular Cancer Research 13 (3), 493-501, 2015 | 75 | 2015 |
| Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation K Erdélyi, T Ditrói, HJ Johansson, Á Czikora, N Balog, L Silwal-Pandit, ... Proceedings of the National Academy of Sciences 118 (45), e2100050118, 2021 | 56 | 2021 |
| TP53 status as a determinant of pro-vs anti-tumorigenic effects of estrogen receptor-beta in breast cancer UK Mukhopadhyay, CC Oturkar, C Adams, N Wickramasekera, S Bansal, ... JNCI: Journal of the National Cancer Institute 111 (11), 1202-1215, 2019 | 48 | 2019 |
| The longitudinal transcriptional response to neoadjuvant chemotherapy with and without bevacizumab in breast cancer L Silwal-Pandit, S Nord, H von der Lippe Gythfeldt, EK Møller, T Fleischer, ... Clinical Cancer Research 23 (16), 4662-4670, 2017 | 42 | 2017 |
| Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases O Østrup, VJ Dagenborg, EA Rødland, V Skarpeteig, L Silwal-Pandit, ... Oncotarget 8 (44), 76290, 2017 | 34 | 2017 |
| The sub-cellular localization of WRAP53 has prognostic impact in breast cancer L Silwal-Pandit, H Russnes, E Borgen, V Skarpeteig, HK Moen Vollan, ... PloS one 10 (10), e0139965, 2015 | 28 | 2015 |
| Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy LR Euceda, TH Haukaas, GF Giskeødegård, R Vettukattil, J Engel, ... Metabolomics 13, 1-14, 2017 | 26 | 2017 |
| Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations EK Höglander, S Nord, DC Wedge, OC Lingjærde, L Silwal-Pandit, ... Genome medicine 10, 1-14, 2018 | 24 | 2018 |
| Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer K Krüger, L Silwal-Pandit, E Wik, O Straume, IM Stefansson, E Borgen, ... Scientific Reports 11 (1), 3388, 2021 | 20 | 2021 |
| Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate AH Ree, HG Russnes, D Heinrich, S Dueland, K Boye, V Nygaard, ... ESMO open 2 (2), e000158, 2017 | 17 | 2017 |
| Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER‐positive breast cancer H von der Lippe Gythfeldt, T Lien, X Tekpli, L Silwal‐Pandit, E Borgen, ... International Journal of Cancer 147 (9), 2515-2525, 2020 | 15 | 2020 |
| Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk N Samuel, B Id Said, T Guha, A Novokmet, W Li, L Silwal‐Pandit, ... Human mutation 38 (3), 265-268, 2017 | 11 | 2017 |
| Proteome analysis of pancreatic tumors implicates extracellular matrix in patient outcome L Silwal-Pandit, SM Stålberg, HJ Johansson, G Mermelekas, IMB Lothe, ... Cancer Research Communications 2 (6), 434-446, 2022 | 5 | 2022 |
| Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma A Khadse, VD Haakensen, L Silwal-Pandit, J Hamfjord, P Micke, J Botling, ... Frontiers in oncology 12, 873532, 2022 | 4 | 2022 |
| Proteomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPPA) results from NeoAva-a randomized … MH Haugen, OC Lingjaerde, M Krohn, EM Lindholm, L Silwal-Pandit, ... Cancer Research 76 (14_Supplement), 3268-3268, 2016 | 3 | 2016 |
| An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer T Fleischer, MH Haugen, J Ankill, L Silwal‐Pandit, AL Børresen‐Dale, ... Molecular Oncology, 2024 | 1 | 2024 |
